Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
LILRB4 is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. De plus, nous expédions et LILRB4 Kits (30) et beaucoup plus de produits pour cette protéine.
Showing 10 out of 78 products:
Human Monoclonal LILRB4 Primary Antibody pour FACS - ABIN4895889
Zimmer, Luce, Gaignier, Nony, Naveau, Biola-Vidamment, Pallardy, Van Overtvelt, Mascarell, Moingeon: Identification of a new phenotype of tolerogenic human dendritic cells induced by fungal proteases from Aspergillus oryzae. dans Journal of immunology (Baltimore, Md. : 1950) 2011
Show all 5 Pubmed References
Human Polyclonal LILRB4 Primary Antibody pour FACS, WB - ABIN4899298
Waschbisch, Sanderson, Krumbholz, Vlad, Theil, Schwab, Mäurer, Derfuss: Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients. dans PLoS ONE 2015
Show all 4 Pubmed References
Human Monoclonal LILRB4 Primary Antibody pour FACS - ABIN4895887
Ulges, Klein, Reuter, Gerlitzki, Hoffmann, Grebe, Staudt, Stergiou, Bohn, Brühl, Muth, Yurugi, Rajalingam, Bellinghausen, Tuettenberg, Hahn, Reißig, Haben, Zipp, Waisman, Probst, Beilhack, Buchou et al.: Protein kinase CK2 enables regulatory T cells to suppress excessive TH2 responses in vivo. ... dans Nature immunology 2015
Show all 3 Pubmed References
Human Polyclonal LILRB4 Primary Antibody pour CyTOF, FACS - ABIN4899300
Gleissner, Zastrow, Klingenberg, Kluger, Konstandin, Celik, Haemmerling, Shankar, Giese, Katus, Dengler: IL-10 inhibits endothelium-dependent T cell costimulation by up-regulation of ILT3/4 in human vascular endothelial cells. dans European journal of immunology 2006
These results suggest that tyrosine phosphorylation may be critical in FcgammaRI (Montrer FCGR1A Anticorps)-dependent endocytosis/phagocytosis that may be regulated by LILRB4 by triggering dephosphorylation of key signalling proteins.
ILT3 may functionally contribute to a regulatory network controlling tumor progression by suppressing the Akt (Montrer AKT1 Anticorps) pathway.
The ILT3 PBs (Montrer TSPO Anticorps)/PCs were suggested to be developmentally equivalent based on the simultaneous generation of these populations upon activation of memory B cells in vitro ILT3 expression was found to be induced efficiently by IL-2 (Montrer IL2 Anticorps), while IFN-alpha effectively induced ILT3 PBs (Montrer TSPO Anticorps)/PCs in vitro Utilizing the elevated ILT3 will support opening a new avenue for molecular markers for, pathogenic cells.
this study shows that LILRB4 might have dual inhibitory and activating functions, depending on the position of the functional tyrosine residues in its immunoreceptor tyrosine-based inhibitory motifs and/or the nature of the stimuli
LILRB4 expression is significantly upregulated in human masticatory mucosa during wound healing
Identification of ILT4 (Montrer LILRB2 Anticorps) as a cellular receptor for CSP (Montrer DNAJC5 Anticorps) C4d
involvement of ILT3 and ILT4 in the modulation of immune responsiveness in multiple sclerosis by both interferon and vitamin D
Cyclosporine up-regulated the expression of ILT3 and ILT4 (Montrer LILRB2 Anticorps) on natural killer cells, which influenced their cytotoxicity against tumor cells.
Crystal structure of leukocyte Ig-like receptor (Montrer LILRA6 Anticorps) LILRB4 (ILT3/LIR-5/CD85k): a myeloid inhibitory receptor involved in immune tolerance.
Data show that LILRB4 is a potent inhibitor of monocyte activation via FcgammaRI (Montrer FCGR1A Anticorps).
Targeting hepatic LILRB4 to improve its expression or activation represents a promising strategy for the treatment of non alcoholic fatty liver diseases as well as related liver and metabolic diseases
Results suggest that plasma cell development from memory and marginal zone B cells, as well as subsequent antibody production, are suppressed via glycoprotein 49B (gp49B).
LILRB4 can downregulate the development of pathologic allergic inflammation.
receptor attenuates the number of these mature DCs and attendant IL-4 (Montrer IL4 Anticorps)-producing lymphocytes in the lymph nodes, and accordingly, the ability of DCs to elicit pathologic Th2 pulmonary inflammation
Gp49B1 is a unique inhibitory receptor that is induced in multiple lineages of innate and adaptive immune cells during an infection and controls their IFN-gamma (Montrer IFNG Anticorps), but not cytotoxic responses.
Expression of gp49B was detected on peripheral eosinophils of control mice and on eosinophils from lungs of mice treated with RW, suggesting a role for gp49B on eosinophils in dampening allergic inflammatory responses.
study reports that gp49B, is expressed on dendritic cells and downregulates cellular activity to prevent the excessive activation of T cells in vitro and in vivo
This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The receptor is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. It is thought to control inflammatory responses and cytotoxicity to help focus the immune response and limit autoreactivity. Multiple transcript variants encoding different isoforms have been found for this gene.
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4
, CD85 antigen-like family member K
, immunoglobulin-like transcript 3
, leukocyte immunoglobulin-like receptor 5
, leukocyte immunoglobulin-like receptor subfamily B member 4
, monocyte inhibitory receptor HM18
, glycoprotein 49 B
, mast cell surface glycoprotein Gp49B